B-cell specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhancing tumor immune evasion
Asslaber, D; Qi, Y; Maeding, N; Denk, U; Hopner, JP; Hartmann, TN; Zaborsky, N; Greil, R; Egle, A ONCOL RES TREAT. 2019; 42: 17-18.
Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.
Wainberg, ZA; Lassen, UN; Elez, E; Italiano, A; Curigliano, G; De Braud, FG; Prager, G; Greil, R; Stein, A; Fasolo, A; Schellens, JHM; Wen, PY; Boran, AD; Burgess, P; Gasal, E; Ilankumaran, P; Subbiah, V J CLIN ONCOL. 2019; 37(4):
Induction chemotherapy with Docetaxel, Cisplatin and Cetuximab results in improved response rates if compared to Docetaxel, Cisplatin and 5-FU for locally advanced or inoperable squamous cell carcinoma of the head and neck: promising results of the Austrian multicentric phase II trial (AGMT)
Keil, F; Hartl, M; Altorjai, G; Pecherstorfer, M; Berghold, A; Riedl, R; De Vries, A; Mayrbaurl, B; Fridrik, MA; Fureder, T; Burian, M; Greil, R ONCOL RES TREAT. 2019; 42: 56-57.
First data on overall survival of metastatic breast cancer patients in Austria according to breast cancer subtype: results from the AGMT MBC Registry
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R ONCOL RES TREAT. 2019; 42: 40-40.
Unmaintained remission after discontinuation of kinase inhibitor treatment in chronic lymphocytic leukemia: an observational cohort
Egle, A; Jager, U; Skrabs, C; Durig, J; Nosslinger, T; Wanner, D; Steurer, M; Ringshausen, I; Melchardt, T; Greil, R; Ysebaert, L ONCOL RES TREAT. 2019; 42: 18-18.
Cardiovascular events are declining in men with HIV aged 50 years or older in Austria
Rappold, M; Kitchen, M; Rieger, A; Schmied, B; Ollinger, A; Egle, A; Wallner, E; Kanatschnig, M; Zoufaly, A; Ledergerber, B; Zangerle, R HIV MED. 2019; 20: 118-119.
Similar but different: Using combined phylogenies of Austria and Switzerland reveals differences in transmission patterns of the local HIV-1 epidemics
Kusejko, K; Battegay, M; Bernasconi, E; Boni, J; Calmy, A; Cavassini, M; Egle, A; Grabmeier-Pfistershammer, K; Haas, B; Klimkait, T; Ollinger, A; Perreau, M; Ramette, A; Flury, BB; Sarcletti, M; Scherrer, A; Schmid, P; Yerly, S; Zangerle, R; Gunthard, HF; Kouyos, RD HIV MED. 2019; 20: 29-29.
BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Bishop, M; Flinn, I; Borchmann, P; Jaeger, U; Westin, J; Hamad, N; Purtill, D; Greil, R; Thomas, S; Teshima, T; Harigae, H; Garcia, C; Barba, P; Deol, A; Shaughnessy, P; Gu, J; Andreola, G; Prieto, MM; Pacaud, L; Schuster, S J IMMUNOTHER CANCER. 2019; 7:
The hepatitis C continuum of care among HIV-infected individuals in Austria
Rappold, M; Gisinger, M; Chromy, D; Schmied, B; Ollinger, A; Wallner, E; Zoufaly, A; Egle, A; Kanatschnig, M; Zangerle, R HIV MED. 2019; 20: 193-193.
A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.
Schimanski, CC; Kasper, S; Hegewisch-Becker, S; Schroeder, J; Overkamp, F; Kullmann, F; Bechstein, WO; Vohringer, M; Oellinger, R; Lordick, F; Heinemann, V; Geissler, M; Schulz-Abelius, A; Linz, B; Bernhard, H; Schoen, MR; Greil, R; Smith-Machnow, V; Schmidtmann, I; Moehler, MH J CLIN ONCOL. 2019; 37(4):
